Jump to content

ACSF3

From Wikipedia, the free encyclopedia

ACSF3
Identifiers
AliasesACSF3, acyl-CoA synthetase family member 3
External IDsOMIM: 614245; MGI: 2182591; HomoloGene: 14958; GeneCards: ACSF3; OMA:ACSF3 - orthologs
Orthologs
SpeciesHumanMouse
Entrez

197322

257633

Ensembl

ENSG00000176715

ENSMUSG00000015016

UniProt

Q4G176

Q3URE1

RefSeq (mRNA)

NM_001127214
NM_001243279
NM_001284316
NM_174917

NM_144932

RefSeq (protein)

NP_001120686
NP_001230208
NP_001271245
NP_777577

NP_659181

Location (UCSC)Chr 16: 89.09 – 89.16 MbChr 8: 122.78 – 122.82 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Acyl-CoA synthetase family member 3 (ACSF3) is a mitochondrial enzyme encoded by the ACSF3 gene.[5] It is required for the degradation of malonic acid and methylmalonic acid and provides the precursor for mitochondrial fatty acid synthesis (mtFAS) and mitochondrial lysine malonylation.[6][7] The enzyme belongs to the acyl-CoA synthetase family.[8]

Structure

[edit]

The ACSF3 gene is located on chromosome 16, at locus q24.3.[9] It comprises 14 exons and produces four alternatively spliced mRNAs that encode two isoforms of the ACSF3 protein:[9][10]

Isoform 1

[edit]

Three transcript variants encode a 576-amino acid protein of about 64.1 kDa with a predicted N-terminal mitochondrial targeting sequence (MTS) comprising the first 58 or 83 residues depending on the prediction method.[9][11][12][13] Experimental studies confirmed that the mature protein localizes to the mitochondrial matrix.[14][7]

Observed post-translational modifications:

Isoform 2

[edit]

A single transcript variant encodes a shorter 311-amino-acid protein that begins translation at a downstream start codon relative to isoform 1.[10][9]

Reaction

[edit]

ACSF3 differs from acyl-CoA synthetases that activate fatty acids by preferring the dicarboxylic acids malonate and methylmalonate, which it converts into the thioesters malonyl-CoA and methylmalonyl-CoA.[14][16] Lignoceric acid (C24) has been reported as an additional substrate, although in vitro studies provide conflicting results.[8][12][14] Despite this substrate specificity, it follows the same two-step ATP-dependent mechanism as other acyl-CoA synthetases via an acyl-adenylate intermediate:[17]

  1. Adenylation step: The carboxylate group of the substrate malonate or methylmalonate attacks the α-phosphate of ATP in its Mg2+-bound form (Mg-ATP), forming the high-energy intermediate malonyl-AMP or methylmalonyl-AMP and diphosphate (PPi). During this step, the magnesium ion coordinates the β- and γ-phosphates of ATP and stabilizes their negative charges, as conserved among all acyl-CoA synthetases.[17][18]
  2. Thioesterification step: The thiol group of coenzyme A (CoA, often written as CoA-SH in its free form) attacks malonyl-AMP or methylmalonyl-AMP, displacing AMP and forming the corresponding thioester, malonyl-CoA or methylmalonyl-CoA.

Accordingly, ACSF3 catalyzes the following overall reactions:

ATP + malonate + CoA → AMP + diphosphate + malonyl-CoA
ATP + methylmalonate + CoA → AMP + diphosphate + methylmalonyl-CoA

ACSF3 most efficiently converts malonate and processes methylmalonate at about 70% of that rate.[14] Like other acyl-CoA synthetases, ACSF3 activity is subject to feedback inhibition by its products.[7]

Function

[edit]

Analogous to the overall reactions described above, the following subsections describe the functional role of ACSF3, starting with the upstream substrates malonic acid and methylmalonic acid and proceeding to the downstream products malonyl-CoA and methylmalonyl-CoA.

Degradation of malonic acid

[edit]

The mitochondrial origin of malonic acid is unknown, but it crosses plasma membranes only to a limited extent, with uptake increasing under acidic conditions, and enters mitochondria via the dicarboxylate carrier SLC25A10.[14][19] A major source is thought to be non-enzymatic hydrolysis of cytosolic malonyl-CoA from de novo fatty acid synthesis, with levels correlating to lipogenic activity.[7] Additional contributions may come from acyl-CoA thioesterases, acetyl-CoA carboxylation, oxaloacetate decarboxylation, malondialdehyde oxidation, and β-alanine metabolism.[7] Exogenous contributions can also derive from the diet, as free malonic acid occurs in plants such as legumes.[14]

By converting malonic acid into malonyl-CoA, ACSF3 plays a critical role in clearing intramitochondrial malonate, a potent inhibitor of mitochondrial respiration.[20][7] Malonate competitively inhibits succinate dehydrogenase (SDH), an enzyme that functions both in the citric acid cycle (TCA cycle) and as Complex II of the electron transport chain.[20][7] Through this activity, ACSF3 performs a metabolic editing function that prevents malonate toxicity and enables highly metabolically active cells to sustain respiration.[7]

Degradation of methylmalonic acid

[edit]
The role of ACSF3 in the propionate metabolism pathway within mitochondria.

Methylmalonic acid is formed as a byproduct through the hydrolysis of methylmalonyl-CoA in the propionate metabolism pathway and is recycled by ACSF3 to methylmalonyl-CoA, feeding back into the pathway.[21][22] According to an Acsf3 knockout mouse model, threonine catabolism was identified as the major contributor to the accumulation of methylmalonic acid.[23]

Efficient clearance of both malonic and methylmalonic acid is required to maintain mitochondrial function and to prevent metabolic acidosis.[23][11] Specifically, methylmalonic acid impairs SDH activity indirectly by interfering with mitochondrial succinate import rather than by direct enzymatic inhibition.[24] In mouse osteoblast cell models, it suppressed osteogenic differentiation and bone matrix mineralization by downregulating osteogenic marker genes, linking ACSF3-mediated methylmalonic acid clearance to bone formation.[23]

Synthesis of mitochondrial malonyl-CoA

[edit]

Since malonyl-CoA is a membrane-impermeable intermediate, it requires local synthesis within mitochondria.[14] Although the exact origin of mitochondrial malonyl-CoA remains debated, the pool is thought to be provided by ACSF3 from malonic acid and by the mitochondrial isoform of acetyl-CoA carboxylase 1 (mtACC1) from acetyl-CoA.[25][26] Mitochondrial malonyl-CoA is required for mitochondrial fatty acid synthesis, lysine malonylation and acetyl-CoA synthesis.[6][20]

Mitochondrial fatty acid synthesis (mtFAS)

[edit]
The role of ACSF3 in the mitochondrial fatty acid synthesis pathway.

In nutrient-responsive mitochondrial fatty acid synthesis (mtFAS), malonyl-CoA serves as the precursor of the chain extender unit malonyl-ACP (C3), which, in a condensation reaction with CO2 release, elongates the ACP-bound fatty acid chain by two carbons per round.[25][14][27] The resulting acyl-ACP species serve different functions depending on their chain length: for example, octanoyl-ACP (C8) is required for the biosynthesis of lipoic acid, a cofactor of key mitochondrial multienzyme complexes such as the pyruvate dehydrogenase complex (PDC), the 2-oxoglutarate dehydrogenase complex (OGDC), the 2-oxoadipate dehydrogenase complex (OADHC), the branched-chain α-keto acid dehydrogenase complex (BCKDHC), and the glycine cleavage system (GCS).[6] Longer-chain species (C10-16) allosterically activate the network of LYRM proteins.[28][29] In humans, this network comprises at least 12 proteins and regulates mitochondrial translation, iron–sulfur cluster biogenesis, and the assembly of electron transport chain complexes.[30][29]

Lysine malonylation

[edit]
Main article: Lysine malonylation

Lysine malonylation is a dynamic post-translational modification in which malonyl-CoA donates malonyl groups to lysine residues, reversing their positive charge and increasing steric bulk.[31] This can alter protein conformation, activity, and protein–protein interactions, and has been linked to energy metabolism, especially glycolysis and β-oxidation.[32] ACSF3 regulates the feeding-dependent rhythmic lysine malonylation of mitochondrial proteins by controlling the availability of malonyl-CoA, thereby modulating hepatic pathways such as glycogen mobilization, lipid synthesis, and triglyceride accumulation.[33] The extent of lysine malonylation has been reported to vary across different cell types.[23]

Synthesis of acetyl-CoA

[edit]

The conversion of malonyl-CoA to acetyl-CoA by malonyl-CoA decarboxylase (MCD), which then can feed into the TCA cycle, completes the malonic acid degradation pathway.[33][7] Simultaneously, this limits malonyl-CoA accumulation, which is thought to inhibit ACSF3 through product feedback, and thereby helps maintain malonic acid clearance via this pathway.[7]

Synthesis of mitochondrial methylmalonyl-CoA

[edit]

Methylmalonyl-CoA is also a membrane-impermeable intermediate and must therefore be synthesized locally within mitochondria.[34] The mitochondrial methylmalonyl-CoA pool is supplied by the propionate metabolism pathway, with additional contributions from ACSF3 by activating methylmalonic acid.[21] Methylmalonyl-CoA is required for synthesis of succinyl-CoA and lysine methylmalonylation.

Synthesis of succinyl-CoA

[edit]

The conversion of methylmalonyl-CoA to succinyl-CoA by methylmalonyl-CoA mutase supports anaplerotic replenishment of TCA cycle intermediates.[35] The importance varies with tissue type and metabolite levels and is particularly pronounced in the brain, where maintaining the α-ketoglutarate pool supports the production of GABA and glutamine.[35] Mitochondrial succinyl-CoA is also essential for substrate-level phosphorylation in the TCA cycle, heme biosynthesis, ketone body utilization, and lysine succinylation.[36]

Lysine methylmalonylation

[edit]

Lysine methylmalonylation, a pathogenic post-translational modification, requires methylmalonyl-CoA as the donor, with ACSF3 contributing to its availability.[37]

Clinical significance

[edit]

Combined malonic and methylmalonic aciduria (CMAMMA)

[edit]

Pathogenic variants in the ACSF3 gene cause the metabolic disorder combined malonic and methylmalonic aciduria (CMAMMA).[11] CMAMMA is a condition characterized by high levels of methylmalonic acid and malonic acid. The disease is typically diagnosed either by genetic testing or biochemically, based on higher levels of methylmalonic acid relative to malonic acid. By calculating the malonic acid to methylmalonic acid ratio in blood plasma, CMAMMA can be distinguished from classic methylmalonic acidemias.[38] The disorder typically presents symptoms early in childhood, first starting with high levels of acid in the blood (ketoacidosis). Other features can include involuntary muscle tensing (dystonia), weak muscle tone (hypotonia), developmental delay, an inability to grow and gain weight at the expected rate (failure to thrive), low blood sugar (hypoglycemia), and coma. Some affected children can even have microcephaly. Other people with CMAMMA do not develop signs and symptoms until adulthood. These individuals usually have neurological problems, such as seizures, loss of memory, a decline in thinking ability, or psychiatric diseases.[5]

Chronic obstructive pulmonary disease (COPD)

[edit]

An epigenetic study found differential DNA methylation of the ACSF3 gene in fetal lung tissue exposed to maternal smoking, suggesting a potential role in the developmental origins of chronic obstructive pulmonary disease (COPD).[39] Furthermore, integrative analyses of lung tissue DNA methylation and gene expression have identified ACSF3 as a key regulator of COPD.[39]

Metabolic dysfunction-associated steatotic liver disease (MASLD)

[edit]

ACSF3 is involved in the pathophysiology of metabolic dysfunction–associated steatotic liver disease (MASLD, formerly NAFLD).[15] Its expression is increased in mouse models of a high-fat diet as well as in the diseases obesity and alcoholic liver disease, both of which are associated with impaired mitochondrial fatty acid metabolism and increased lipid peroxidation.[15] Deacetylation of ACSF3 by the mitochondrial deacetylase sirtuin 3 (SIRT3) leads to decreased stability and promotes degradation of ACSF3, which, under high-fat diet conditions, improves hepatic lipid homeostasis and reduces steatosis in mouse models.[15] The phenolic compound protocatechuic acid (PCA) has been shown to activate SIRT3, highlighting the SIRT3–ACSF3 axis as a potential therapeutic target for MASLD.[15][40]

Evolutionary role

[edit]

The ancient human-specific regulatory variant rs34590044-A upregulates ACSF3 expression and is associated with increased height and basal metabolic rate (BMR).[23] Anatomically modern humans show greater height and higher mass-adjusted BMR than non-human great apes, a difference interpreted as adaptation to meat-rich diets via enhanced threonine metabolism and reduced accumulation of methylmalonic acid.[23] Functional studies in human cells and mouse models demonstrate that ACSF3 is essential for maintaining mitochondrial activity and indirectly affects osteogenesis by limiting methylmalonic acid accumulation, thereby linking human metabolism, height, and diet.[23]

See also

[edit]

References

[edit]
  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000176715 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000015016 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ a b "Entrez Gene: Acyl-CoA synthetase family member 3". Retrieved 2011-12-30.
  6. ^ a b c Wehbe Z, Behringer S, Alatibi K, Watkins D, Rosenblatt D, Spiekerkoetter U, et al. (2019-11-01). "The emerging role of the mitochondrial fatty-acid synthase (mtFASII) in the regulation of energy metabolism". Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1864 (11): 1629–1643. doi:10.1016/j.bbalip.2019.07.012. ISSN 1388-1981. PMID 31376476. S2CID 199404906.
  7. ^ a b c d e f g h i j Bowman CE, Wolfgang MJ (January 2019). "Role of the malonyl-CoA synthetase ACSF3 in mitochondrial metabolism". Advances in Biological Regulation. 71: 34–40. doi:10.1016/j.jbior.2018.09.002. PMC 6347522. PMID 30201289.
  8. ^ a b Watkins PA, Maiguel D, Jia Z, Pevsner J (December 2007). "Evidence for 26 distinct acyl-coenzyme A synthetase genes in the human genome". Journal of Lipid Research. 48 (12): 2736–2750. doi:10.1194/jlr.M700378-JLR200. PMID 17762044.
  9. ^ a b c d "ACSF3 acyl-CoA synthetase family member 3 [Homo sapiens (human)]". NCBI Gene. National Center for Biotechnology Information, U.S. National Library of Medicine. Retrieved 2025-09-24.
  10. ^ a b "Synthesis of Fatty Acids". The Medical Biochemistry Page. 15 August 2020. Retrieved 2025-09-24.
  11. ^ a b c Alfares A, Nunez LD, Al-Thihli K, Mitchell J, Melançon S, Anastasio N, et al. (September 2011). "Combined malonic and methylmalonic aciduria: exome sequencing reveals mutations in the ACSF3 gene in patients with a non-classic phenotype". Journal of Medical Genetics. 48 (9): 602–605. doi:10.1136/jmedgenet-2011-100230. PMID 21785126.
  12. ^ a b NIH Intramural Sequencing Center Group, Sloan JL, Johnston JJ, Manoli I, Chandler RJ, Krause C, et al. (September 2011). "Exome sequencing identifies ACSF3 as a cause of combined malonic and methylmalonic aciduria". Nature Genetics. 43 (9): 883–886. doi:10.1038/ng.908. ISSN 1061-4036. PMC 3163731. PMID 21841779.
  13. ^ Wang P, Shu J, Gu C, Yu X, Zheng J, Zhang C, et al. (2021-11-25). "Combined Malonic and Methylmalonic Aciduria Due to ACSF3 Variants Results in Benign Clinical Course in Three Chinese Patients". Frontiers in Pediatrics. 9 751895. doi:10.3389/fped.2021.751895. ISSN 2296-2360. PMC 8658908. PMID 34900860.
  14. ^ a b c d e f g h Witkowski A, Thweatt J, Smith S (September 2011). "Mammalian ACSF3 Protein Is a Malonyl-CoA Synthetase That Supplies the Chain Extender Units for Mitochondrial Fatty Acid Synthesis". The Journal of Biological Chemistry. 286 (39): 33729–33736. doi:10.1074/jbc.M111.291591. PMC 3190830. PMID 21846720.
  15. ^ a b c d e Sun R, Kang X, Zhao Y, Wang Z, Wang R, Fu R, et al. (2020). "Sirtuin 3-mediated deacetylation of acyl-CoA synthetase family member 3 by protocatechuic acid attenuates non-alcoholic fatty liver disease". British Journal of Pharmacology. 177 (18): 4166–4180. doi:10.1111/bph.15159. ISSN 1476-5381. PMC 7443473. PMID 32520409.
  16. ^ Eriksson Ström J, Kebede Merid S, Linder R, Pourazar J, Lindberg A, Melén E, et al. (2025-01-10). "Airway MMP-12 and DNA methylation in COPD: an integrative approach". Respiratory Research. 26 (1): 10. doi:10.1186/s12931-024-03088-3. ISSN 1465-993X. PMC 11724436. PMID 39794761.
  17. ^ a b Gulick AM (2009-10-16). "Conformational Dynamics in the Acyl-CoA Synthetases, Adenylation Domains of Non-ribosomal Peptide Synthetases, and Firefly Luciferase". ACS Chemical Biology. 4 (10): 811–827. doi:10.1021/cb900156h. ISSN 1554-8929. PMC 2769252. PMID 19610673.
  18. ^ Fiorentini D, Cappadone C, Farruggia G, Prata C (2021-03-30). "Magnesium: Biochemistry, Nutrition, Detection, and Social Impact of Diseases Linked to Its Deficiency". Nutrients. 13 (4) 1136. doi:10.3390/nu13041136. ISSN 2072-6643. PMC 8065437. PMID 33808247.
  19. ^ Prag HA, Aksentijevic D, Dannhorn A, Giles AV, Mulvey JF, Sauchanka O, et al. (2022-09-02). "Ischemia-Selective Cardioprotection by Malonate for Ischemia/Reperfusion Injury". Circulation Research. 131 (6): 528–541. doi:10.1161/CIRCRESAHA.121.320717. ISSN 0009-7330. PMC 9426742. PMID 35959683.
  20. ^ a b c Bowman CE, Rodriguez S, Alpergin ES, Acoba MG, Zhao L, Hartung T, et al. (2017-06-22). "The Mammalian Malonyl-CoA Synthetase ACSF3 Is Required for Mitochondrial Protein Malonylation and Metabolic Efficiency". Cell Chemical Biology. 24 (6): 673–684.e4. doi:10.1016/j.chembiol.2017.04.009. ISSN 2451-9456. PMC 5482780. PMID 28479296.
  21. ^ a b Tejero J, Lazure F, Gomes AP (March 2024). "Methylmalonic acid in aging and disease". Trends in Endocrinology & Metabolism. 35 (3): 188–200. doi:10.1016/j.tem.2023.11.001. PMC 10939937. PMID 38030482.
  22. ^ Manoli I, Sloan JL, Venditti CP. Isolated Methylmalonic Acidemia. 2005 Aug 16 [Updated 2022 Sep 8]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025. Figure 1. [Major pathway of the conversion...]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1231/figure/mma.F1/ PMID 20301409. NBK1231
  23. ^ a b c d e f g Zhang Y, Wang J, Yi C, Su Y, Yin Z, Zhang S, et al. (June 2025). "An ancient regulatory variant of ACSF3 influences the coevolution of increased human height and basal metabolic rate via metabolic homeostasis". Cell Genomics. 5 (6) 100855. doi:10.1016/j.xgen.2025.100855. PMC 12230238. PMID 40403731.
  24. ^ Mirandola SR, Melo DR, Schuck PF, Ferreira GC, Wajner M, Castilho RF (2008). "Methylmalonate inhibits succinate-supported oxygen consumption by interfering with mitochondrial succinate uptake". Journal of Inherited Metabolic Disease. 31 (1): 44–54. doi:10.1007/s10545-007-0798-1. ISSN 1573-2665. PMID 18213522.
  25. ^ a b Nowinski SM, Van Vranken JG, Dove KK, Rutter J (October 2018). "Impact of Mitochondrial Fatty Acid Synthesis on Mitochondrial Biogenesis". Current Biology. 28 (20): R1212 – R1219. Bibcode:2018CBio...28R1212N. doi:10.1016/j.cub.2018.08.022. PMC 6258005. PMID 30352195.
  26. ^ Monteuuis G, Suomi F, Kerätär JM, Masud AJ, Kastaniotis AJ (2017-11-15). "A conserved mammalian mitochondrial isoform of acetyl-CoA carboxylase ACC1 provides the malonyl-CoA essential for mitochondrial biogenesis in tandem with ACSF3". The Biochemical Journal. 474 (22): 3783–3797. doi:10.1042/BCJ20170416. ISSN 0264-6021. PMID 28986507.
  27. ^ Nowinski SM, Solmonson A, Rusin SF, Maschek JA, Bensard CL, Fogarty S, et al. (2020-08-17). "Mitochondrial fatty acid synthesis coordinates oxidative metabolism in mammalian mitochondria". eLife. 9 e58041. doi:10.7554/eLife.58041. ISSN 2050-084X. PMC 7470841. PMID 32804083.
  28. ^ Tang JX, Thompson K, Taylor RW, Oláhová M (2020-05-28). "Mitochondrial OXPHOS Biogenesis: Co-Regulation of Protein Synthesis, Import, and Assembly Pathways". International Journal of Molecular Sciences. 21 (11): 3820. doi:10.3390/ijms21113820. ISSN 1422-0067. PMC 7312649. PMID 32481479.
  29. ^ a b Van Vranken JG, Nowinski SM, Clowers KJ, Jeong MY, Ouyang Y, Berg JA, et al. (August 2018). "ACP Acylation Is an Acetyl-CoA-Dependent Modification Required for Electron Transport Chain Assembly". Molecular Cell. 71 (4): 567–580.e4. doi:10.1016/j.molcel.2018.06.039. PMC 6104058. PMID 30118679.
  30. ^ Masud AJ, Kastaniotis AJ, Rahman MT, Autio KJ, Hiltunen JK (December 2019). "Mitochondrial acyl carrier protein (ACP) at the interface of metabolic state sensing and mitochondrial function". Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1866 (12) 118540. BBA. doi:10.1016/j.bbamcr.2019.118540. PMID 31473256.
  31. ^ Hirschey MD, Zhao Y (September 2015). "Metabolic Regulation by Lysine Malonylation, Succinylation, and Glutarylation". Molecular & Cellular Proteomics. 14 (9): 2308–2315. doi:10.1074/mcp.R114.046664. PMC 4563717. PMID 25717114.
  32. ^ Zou L, Yang Y, Wang Z, Fu X, He X, Song J, et al. (2023). "Lysine Malonylation and Its Links to Metabolism and Diseases". Aging and Disease. 14 (1): 84–98. doi:10.14336/AD.2022.0711. ISSN 2152-5250. PMC 9937698. PMID 36818560.
  33. ^ a b Questel EL, Besnard C, Atger F, Foucher Y, Tollec A, Pakulska V, et al. (2024-09-06). "Diurnal regulation of Acyl-CoA synthetase 3 (ACSF3) underlies daily mitochondrial lysine-malonylation and hepatic metabolism". bioRxiv 10.1101/2024.09.03.607283.
  34. ^ Hamilton JA (November 2007). "New insights into the roles of proteins and lipids in membrane transport of fatty acids". Prostaglandins, Leukotrienes and Essential Fatty Acids. 77 (5–6): 355–361. doi:10.1016/j.plefa.2007.10.020. PMID 18032007.
  35. ^ a b Wongkittichote P, Ah Mew N, Chapman KA (December 2017). "Propionyl-CoA carboxylase – A review". Molecular Genetics and Metabolism. 122 (4): 145–152. doi:10.1016/j.ymgme.2017.10.002. PMC 5725275. PMID 29033250.
  36. ^ Lancaster MS, Graham BH (2023-06-27). "Succinyl-CoA Synthetase Dysfunction as a Mechanism of Mitochondrial Encephalomyopathy: More than Just an Oxidative Energy Deficit". International Journal of Molecular Sciences. 24 (13) 10725. doi:10.3390/ijms241310725. ISSN 1422-0067. PMC 10342173. PMID 37445899.
  37. ^ Head PE, Myung S, Chen Y, Schneller JL, Wang C, Duncan N, et al. (2022-05-25). "Aberrant methylmalonylation underlies methylmalonic acidemia and is attenuated by an engineered sirtuin". Science Translational Medicine. 14 (646) eabn4772. doi:10.1126/scitranslmed.abn4772. ISSN 1946-6234. PMC 10468269. PMID 35613279.
  38. ^ de Sain-van der Velden MG, van der Ham M, Jans JJ, Visser G, Prinsen HC, Verhoeven-Duif NM, et al. (2016). Morava E, Baumgartner M, Patterson M, Shamima R (eds.). "A New Approach for Fast Metabolic Diagnostics in CMAMMA". JIMD Reports. 30. Berlin, Heidelberg: Springer: 15–22. doi:10.1007/8904_2016_531. ISBN 978-3-662-53681-0. PMC 5110436. PMID 26915364.
  39. ^ a b Eriksson Ström J, Kebede Merid S, Linder R, Pourazar J, Lindberg A, Melén E, et al. (2025-01-10). "Airway MMP-12 and DNA methylation in COPD: an integrative approach". Respiratory Research. 26 (1) 10. doi:10.1186/s12931-024-03088-3. ISSN 1465-993X. PMC 11724436. PMID 39794761.
  40. ^ Zhang S, Shen C, Di H, Wang Y, Guan F (2025-06-20). "Regulatory Mechanisms of Phenolic Acids in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review". Antioxidants. 14 (7): 760. doi:10.3390/antiox14070760. ISSN 2076-3921. PMC 12291745.

Further reading

[edit]
[edit]

This article incorporates text from the United States National Library of Medicine, which is in the public domain.

Retrieved from "https://en.wikipedia.org/w/index.php?title=ACSF3&oldid=1315164146"